1. Market Research
  2. > Biotechnology Market Trends

Competing in the Global Contract Manufacturing Market

  • October 2013
  • 219 pages
  • Frost & Sullivan
Report ID: 1864403

Summary

Table of Contents

What Pharmaceutical and Biotechnology Companies Want and How to Compete for their Business

The overall objective of this study was to provide contract manufacturing organizations (CMOs) a sound basis for formulating an effective strategy to compete in the market, including areas of opportunities and threats. As far as the market dynamics and CMO selection are concerned, overall satisfaction and likelihood of contract renewal are in the 40–50% range across all product types, indicating opportunity for CMO vendor switching in the future. Of all parameters used in CMO agreements and selection, “volume commitments” ranks as the most important while “capacity and site transfer” ranks second. Overall, pharmaceutical and biotechnology companies prefer to outsource to CMO companies which possess operations in the same region.

Research Objectives

Overall Objective:
To provide contract manufacturing organizations (CMOs) a sound basis for formulating an effective strategy to compete in the market, including areas of opportunities and threats. Specific objectives are as follows:
Objective 1: To calculate pharmaceutical and biotech companies’ current and future strategy and capacity needs.
Objective 2: To understand pharmaceutical and biotech companies’ outsourcing priorities and trends.
Objective 3: To understand pharmaceutical and biotech companies’ perceptions/attitudes toward CMOs.
Objective 4: To determine pharmaceutical and biotech companies’ CMO selection criteria.
Objective 5: To measure pharmaceutical and biotech companies’ price perceptions toward CMOs.
Objective 6: To understand the decision-making dynamics within pharmaceutical and biotech companies. Specifically, to identify key parties involved in outsourcing initiation, evaluation, recommendation, approval, and CMO performance evaluation.
Objective 7: To identify pharmaceutical and biotech companies’ business models.
Objective 8: To compare pharmaceutical and biotech companies’ regional capabilities.
Objective 9: To identify preferred areas related to informational marketing of CMO services (such as information sources, trade journals, and conferences).

Methodology

Methodology
A mixed methodology was utilized for this customer research, with the use of telephone interviews as the primary method (n=X) and a Web-based survey as a secondary measure (n=X).

Sample
A total of X global decision makers of the final drug form contract manufacturing (non-API) process within biotechnology (biotech) or pharmaceutical (pharma) companies were surveyed from November 2012 to January 2013.

Executive Summary

Market dynamics and CMO selection is as follows:
• Overall satisfaction and likelihood of contract renewal are in the X-X% range across all product types, indicating opportunity for CMO vendors switching in the future as the majority of respondents are dissatisfied and do not have intentions to renew.
• Of the top X CMOs, Baxter Biopharma Solutions, Boehringer Ingelheim, and Pfizer CentreSource are rated as having the highest degree of premium pricing which also correlates with these companies having the highest ranking for full service offerings or a broader number of services available.
• Overall, pharmaceutical and biotechnology companies prefer to outsource to CMO companies that possess operations in the same region (i.e. European biotech companies are more likely to select European CMOs).
• Overall, X% of respondents indicated they are likely to partner with a CMO that functions as an external consultant, specifically for manufacturing process consulting expertise.
• Of all parameters used in CMO agreements and selection, volume commitments, ranks as the most important criterion, and capacity and site transfer ranks as second.

Criteria for business that is most or least likely to be outsourced to CMO companies:
• The most prevalent service capabilities being outsourced to CMO companies are packaging, logistics, and clinical trial supply.
• The most prevalent service capability being planned for outsourcing to CMO companies is drug delivery technology services.
• The least likely service capability to be considered for outsourcing is research and development—likely due to concerns regarding competitive intelligence and an inability to select and hire key staff.
• Within the next 5 years, it is expected that the largest proportion of lot sizes for pre-clinical, clinical, and commercial phase manufacturing will remain the same. However, X% expect that commercial phase manufacturing will get larger.

Preferred CMO marketing exposure outlets are defined as follows:
• The most preferred methods for learning about CMO services are tradeshow and conference booths and word of mouth recommendations from colleagues.
• The top trade journal read is Pharmaceutical Outsourcing but other journals closely behind in ranking include Pharmaceutical Manufacturing, Contract Pharma, BioPharm International, and Pharmaceutical Technology.
• The top 2 trade shows attended or planned to be attended are BIO Annual Meeting and AAPS Annual Meeting.
oThe BIO Annual Meeting and Bio Europe ranked the highest for the virtual and emerging category.
• The top 2 e-newsletters read worldwide are Outsourcing Pharma and Fierce Biotech.
• Baxter Biopharma Solutions and Boehringer Ingelheim are the most preferred CMO companies, earning the largest share of preference (X%).
• No single CMO company was able to achieve the highest preference across regions:
oBaxter Biopharma Solutions is the most preferred CMO by US respondents.
oBaxter Biopharma Solutions and AAl Pharma Services are the most preferred CMOs by European respondents.
oDSM is the most preferred CMO from APAC respondents.

CMO prevalence by company and product type:
• Abbott is the most prevalently used company for basic oral solids due to its personnel background and expertise, indicating the high importance of a positive reputation.
• Baxter is the most prevalently used company for injectables due to their overall quality highlighting the importance of quality assurance for injectables which have the highest standards of quality.
• Abbott is the most prevalently used company for liquid dosage compounds, with the core reasons related to manufacturing capacity and personnel background and expertise.

CMO prevalence by company and product type (continued):
• Catalent is the most prevalently used company for advanced oral solids, with overall quality being the core reason.
• No single company dominates mammalian product manufacturing, indicating opportunity for manufacturers with interest in the space.
• Lonza is the most prevalently used company for microbials, with overall quality being the core reason.
• Abbott is the prevalently used company for dermatological formulations, with the core reason related to overall quality.
• GlaxoSmithKline is the most prevalently used company for inhalation therapies, with overall quality and personnel background/expertise being the core reasons.
• GlaxoSmithKline and Sanofi are the most prevalently used for nasal sprays.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
Biotech Flavors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Biotech Flavors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • April 2017
  • by Transparency Market Research

Global Biotech Flavors Market: Overview Transparency Market Research (TMR) offers an eight-year forecast for the global biotech flavors market between 2016 and 2024. The main objective of the report is ...

Next-Generation Sequencing (NGS) Market by Product (Hiseq, Miseq, Hiseq X Ten/X Five, NextSeq500, Ion Proton, PGM, Ions5, PacBio RSII), Services (Targeted, RNA, Exome, De Novo), & Application (Diagnostics, Biomarker, Agriculture) - Global Forecasts to 202

Next-Generation Sequencing (NGS) Market by Product (Hiseq, Miseq, Hiseq X Ten/X Five, NextSeq500, Ion Proton, PGM, Ions5, PacBio RSII), Services (Targeted, RNA, Exome, De Novo), & Application (Diagnostics, Biomarker, Agriculture) - Global Forecasts to 202

  • $ 5650
  • Industry report
  • April 2017
  • by MarketsandMarkets

The global next-generation sequencing market is estimated to register a CAGR of 20.5% from 2017 to 2022 to reach USD 12.45 billion by 2022. Factors such as technological advancements in NGS platforms, ...

High Throughput Process Development Market by Product & Service (Instrument, Software and Service), Molecule Type (Monoclonal Antibodies, Recombinant Insulin), Process (Upstream, Downstream), End User - Forecast to 2021

High Throughput Process Development Market by Product & Service (Instrument, Software and Service), Molecule Type (Monoclonal Antibodies, Recombinant Insulin), Process (Upstream, Downstream), End User - Forecast to 2021

  • $ 5650
  • Industry report
  • April 2017
  • by MarketsandMarkets

The global high throughput process development market is expected to reach USD 19.78 billion in 2021 from USD 9.91 billion in 2016, at a CAGR of 14.8% from 2016 to 2021. Growth in the high throughput process ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.